ClinicalTrials.gg

Program

povorcitinib

Also written as “Povorcitinib” and “INCB054707”.

Its studies are mostly in Hidradenitis Suppurativa · Prurigo · Vitiligo · Renal Insufficiency · Asthma, led by Incyte.

Furthest: phase 3, since Nov 10, 202223 company-led studies, 8 open or runningNext primary completion: Nov 20, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte238 open or runningphase 3since Nov 10, 2022May 24, 2018Nov 20, 2026phase 2 · NCT05851443

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since May 24, 2018.

  1. Sep 27, 2021Phase 1 study in Healthy ParticipantsNCT05068466 · 30 enrolled · Japan
  2. Nov 10, 20222 phase 3 studies in Hidradenitis SuppurativaNCT05620836, NCT05620823
  3. Nov 11, 20222 phase 1 studies in Renal InsufficiencyNCT05624723, NCT05624710
  4. Apr 24, 2023Phase 2 study in AsthmaNCT05851443 · 247 enrolled · United States, Argentina, Canada and more
  5. Jun 26, 2023Phase 2 study in UrticariaNCT05936567 · 136 enrolled · United States, Germany, Poland
  6. Oct 27, 20232 phase 3 studies in NonSegmental VitiligoNCT06113471, NCT06113445
  7. Jan 9, 2024Phase 3 study in Hidradenitis SuppurativaNCT06212999 · 617 enrolled · United States, Australia, Austria and more
  8. Apr 3, 2024Phase 1 study in Healthy ParticipantsNCT06380205 · 24 enrolled · United States
  9. May 29, 2024Phase 1 study in Healthy ParticipantsNCT06441318 · 128 enrolled · United States
  10. Jul 8, 2024Phase 1 study in Healthy ParticipantsNCT06505265 · 18 enrolled · United States
  11. Jul 18, 20242 phase 3 studies in Prurigo NodularisNCT06516965, NCT06516952
  12. Feb 26, 2025Phase 3 study in Hidradenitis SuppurativaNCT06855498 · 600 planned · United States, Argentina, Australia and more
  13. Oct 7, 2025Phase 2 study in Hidradenitis SuppurativaNCT07213973 · 40 planned · United States, Canada
  14. May 8, 2026Phase 1 study in Healthy ParticipantsNCT07588139 · 24 enrolled · United States

Ahead

  1. Nov 20, 2026Primary completion: phase 2 study in AsthmaNCT05851443
  2. Dec 26, 2026Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06212999
  3. Feb 28, 2028Primary completion: phase 3 study in Hidradenitis SuppurativaNCT06855498
  4. Mar 25, 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07213973

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07588139Healthy Participants · United States1CompletedSep 8, 202624
NCT07213973Hidradenitis Suppurativa · United States, Canada2RecruitingMar 25, 202840
NCT06855498Hidradenitis Suppurativa · United States, Argentina, Australia and more3RecruitingFeb 28, 2028600
NCT06516965Prurigo Nodularis · United States, Australia, Belgium and more3Active, not recruitingSep 28, 2026346
NCT06516952Prurigo Nodularis · United States, Argentina, Austria and more3Active, not recruitingOct 19, 2026349
NCT06505265Healthy Participants · United States1CompletedSep 18, 202418
NCT06441318Healthy Participants · United States1CompletedSep 10, 2024128
NCT06380205Healthy Participants · United States1CompletedJun 7, 202424
NCT06212999Hidradenitis Suppurativa · United States, Australia, Austria and more3Active, not recruitingDec 26, 2026617
NCT06113471NonSegmental Vitiligo · United States, Bulgaria, Canada and more3Active, not recruitingMar 17, 2026450
NCT06113445NonSegmental Vitiligo · United States, Belgium, Canada and more3Active, not recruitingFeb 24, 2026467
NCT05936567Urticaria · United States, Germany, Poland2CompletedFeb 28, 2025136
NCT05851443Asthma · United States, Argentina, Canada and more2Active, not recruitingNov 20, 2026247
NCT05624723Renal Insufficiency · United States, Germany1CompletedFeb 7, 202443
NCT05624710Renal Insufficiency · United States, Germany1CompletedJun 30, 202325
NCT05620836Hidradenitis Suppurativa · United States, Australia, Bulgaria and more3CompletedJan 7, 2025619
NCT05620823Hidradenitis Suppurativa · United States, Austria, Belgium and more3CompletedFeb 3, 2025608
NCT05068466Healthy Participants · Japan1CompletedJan 25, 202230
NCT05061693Prurigo Nodularis · United States, Canada, Germany and more2CompletedAug 11, 2023146
NCT04818346NonSegmental Vitiligo · United States, Canada2CompletedMay 24, 2022171
NCT04476043Hidradenitis Suppurativa · United States, Canada, France and more2CompletedDec 15, 2021209
NCT03607487Hidradenitis Suppurativa · Canada, Denmark, Germany2CompletedAug 13, 201935
NCT03569371Hidradenitis Suppurativa · United States2CompletedApr 22, 201910

How it is read

Names in the registry

  • “Povorcitinib”, 13 entries
  • “INCB054707”, 8 entries
  • “povorcitinib”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.